A stem cell transplant from a compatible donor is often the best hope for patients with leukemia and other cancers. But these treatments often come with long-lasting and even fatal side effects, such as graft-versus-host disease (GvHD). Orca Bio lowers the risk of GvHD by identifying the donor cells with real therapeutic benefits and screening out the rest, providing transplant recipients with a designer immune system.
News & Insights
Explore Companies
Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
Noetik
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Solu Therapeutics
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules